Find clinical trials for Multiple Myeloma in Roma, Lazio
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Multiple Myeloma trials near Roma, Lazio, ITA:
This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine...
Phase 2
Roma, Italy and 24 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Roma, Italy and 117 other locations
low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple...
Phase 3
Rome, Italy and 156 other locations
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM r...
Phase 1
Rome, Lazio, Italy and 18 other locations
monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...
Phase 3
Roma, Italy and 210 other locations
phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...
Phase 1
Roma, Lazio, Italy and 34 other locations
combination with DEX for Relapsed Refractory Multiple Myeloma (RRMM), CC-220 in combination with DEX and BTZ, and CC-220 in combin ...
Phase 1, Phase 2
Rome, Italy and 88 other locations
(Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma...
Phase 3
Roma, Lazio, Italy and 150 other locations
(Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple...
Phase 3
Roma, Lazio, Italy and 129 other locations
This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participant...
Phase 3
Roma, Lazio, Italy and 140 other locations
Clinical trials
Research sites
Resources
Legal